Related Experiment Video

Updated: Jun 23, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component

Jean Claude Osselaer1, Chantal Doyen, Laurence Defoin

  • 1The Transfusion Center, Cliniques Universitaires de Mont Godinne, Université Catholique de Louvain, Yvoir, Belgium.

Transfusion
|April 25, 2009
PubMed

Insights

Pathogen inactivation of platelet components did not affect their use or red blood cell component use. This safety measure did not alter transfusion practices in a blood center over a three-year period.

Area of Science:

  • Transfusion Medicine
  • Blood Banking
  • Infectious Disease Control

Background:

  • Pathogen inactivation technology for platelet components (using the INTERCEPT Blood System) was integrated into clinical practice.
  • This implementation occurred at a blood center serving a major tertiary care hospital.
  • The study aimed to evaluate the impact of this technology on blood component utilization.

Purpose of the Study:

  • To assess the effect of pathogen inactivation on the utilization of platelet components (PCs) and red blood cell (RBC) components.
  • To compare component use in the three years before and three years after the introduction of pathogen inactivation.
  • To analyze clinical outcomes related to component use in a real-world setting.

Main Methods:

  • A retrospective analysis of prospectively collected hemovigilance data was performed.
  • Electronic blood bank records were used to monitor the production and use of blood components.
  • Transfusion records for patients receiving conventional PCs and pathogen-inactivated PCs were analyzed.

Main Results:

  • No significant differences were observed in the mean number of PCs used per patient between conventional and pathogen-inactivated groups (9.9 vs. 10.1).
  • Intensively transfused hematology patients showed no difference in days of platelet support or total platelet dose.
  • Red blood cell component use remained consistent, regardless of patient group or timing relative to platelet transfusions.

Conclusions:

  • Pathogen inactivation of platelet components did not adversely affect component utilization in routine clinical practice.
  • The implementation of pathogen inactivation technology did not lead to changes in transfusion patterns for platelets or red blood cells.
  • The findings support the safe integration of pathogen inactivation into blood banking services without impacting component demand.
Abstract

More Related Videos

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...